MetLife's Q3 Net Income Dips 19.8% Amid Rising Derivative Losses

TL;DR

**MetLife's Q3 earnings are a red flag, with derivative losses eating into profits despite revenue growth; I'm bearish on short-term upside.**

AI Summary

MetLife, Inc. reported a significant decrease in net income attributable to common shareholders for the nine months ended September 30, 2025, falling to $2,395 million from $2,987 million in the prior year, a 19.8% decline. Total revenues also saw a slight increase to $53,270 million from $52,320 million, primarily driven by higher net investment income of $16,635 million in 2025 compared to $15,868 million in 2024. However, this was offset by substantial net derivative losses of $1,293 million in 2025, a significant deterioration from a loss of $720 million in 2024. The company's total assets grew to $719,726 million as of September 30, 2025, up from $677,457 million at December 31, 2024, with fixed maturity securities available-for-sale increasing to $304,645 million from $281,043 million. Share repurchases continued, with treasury stock acquired totaling $2,423 million for the nine months ended September 30, 2025, contributing to a decrease in outstanding common shares. The company also redeemed preferred stock totaling $988 million during the period. Policyholder account balances increased to $235,312 million from $221,445 million, indicating growth in customer deposits. Despite revenue growth, increased expenses, particularly policyholder benefits and claims at $32,942 million, and interest credited to policyholder account balances at $6,608 million, impacted profitability.

Why It Matters

MetLife's 19.8% drop in net income available to common shareholders, despite overall revenue growth, signals potential challenges in managing market volatility and derivative exposures. For investors, this could translate to reduced earnings per share and pressure on future dividend growth, especially given the ongoing share repurchases. Employees might face increased scrutiny on performance and cost controls as the company navigates profitability headwinds. Customers, however, benefit from growing policyholder account balances, indicating continued trust and product appeal in a competitive insurance market. The broader market will watch how MetLife, a major player, manages its investment portfolio and derivative strategies in a fluctuating economic environment, potentially influencing sector-wide risk management practices.

Risk Assessment

Risk Level: medium — The company reported significant net derivative losses of $1,293 million for the nine months ended September 30, 2025, a substantial increase from $720 million in the prior year, indicating heightened market risk exposure. Additionally, the allowance for credit loss on mortgage loans increased to $1,261 million from $800 million, suggesting potential deterioration in asset quality.

Analyst Insight

Investors should scrutinize MetLife's derivative hedging strategies and overall investment portfolio given the substantial net derivative losses. Consider a cautious approach, potentially re-evaluating exposure until there's clearer evidence of improved risk management and sustained profitability.

Financial Highlights

debt To Equity

N/A

revenue

$53.27B

operating Margin

N/A

total Assets

$719.73B

total Debt

$19.46B

net Income

$2.40B

eps

$3.56

gross Margin

N/A

cash Position

$20.23B

revenue Growth

+1.8%

Revenue Breakdown

Key Numbers

• $2.40B — Net Income Available to Common Shareholders (Decreased by 19.8% from $2.99 billion in 2024 to $2.40 billion in 2025 for the nine-month period.)
• $53.27B — Total Revenues (Increased by 1.8% from $52.32 billion in 2024 to $53.27 billion in 2025 for the nine-month period.)
• $1.29B — Net Derivative Losses (Increased significantly from $720 million in 2024 to $1.29 billion in 2025 for the nine-month period.)
• $719.73B — Total Assets (Increased by 6.2% from $677.46 billion at December 31, 2024, to $719.73 billion at September 30, 2025.)
• $2.42B — Treasury Stock Acquired (Represents share repurchases for the nine months ended September 30, 2025.)
• $988M — Preferred Stock Redemption (Amount of preferred stock redeemed during the nine months ended September 30, 2025.)
• $1.23 — Basic EPS (Q3 2025) (Decreased from $1.82 in Q3 2024, reflecting lower net income.)
• $3.56 — Basic EPS (YTD 2025) (Decreased from $4.20 in YTD 2024, reflecting lower net income.)
• $16.64B — Net Investment Income (Increased from $15.87 billion in 2024 to $16.64 billion in 2025 for the nine-month period.)
• $1,261M — Allowance for Credit Loss on Mortgage Loans (Increased from $800 million at December 31, 2024, to $1,261 million at September 30, 2025.)

Key Players & Entities

• MetLife, Inc. (company) — registrant
• $2,395 million (dollar_amount) — Net income available to MetLife, Inc.'s common shareholders for nine months ended September 30, 2025
• $2,987 million (dollar_amount) — Net income available to MetLife, Inc.'s common shareholders for nine months ended September 30, 2024
• $53,270 million (dollar_amount) — Total revenues for nine months ended September 30, 2025
• $52,320 million (dollar_amount) — Total revenues for nine months ended September 30, 2024
• $1,293 million (dollar_amount) — Net derivative losses for nine months ended September 30, 2025
• $720 million (dollar_amount) — Net derivative losses for nine months ended September 30, 2024
• $719,726 million (dollar_amount) — Total assets as of September 30, 2025
• $677,457 million (dollar_amount) — Total assets as of December 31, 2024
• $2,423 million (dollar_amount) — Treasury stock acquired in connection with share repurchases for nine months ended September 30, 2025

FAQ

Risk Factors

• Net Derivative Losses [high — financial]: The company experienced significant net derivative losses of $1,293 million for the nine months ended September 30, 2025, a substantial increase from $720 million in the prior year. This deterioration in derivative performance negatively impacted net income.
• Increased Policyholder Benefits and Claims [medium — financial]: Policyholder benefits and claims increased to $32,942 million for the nine months ended September 30, 2025, from an unstated prior year amount. This rise in claims expense directly reduced profitability.
• Rising Interest Credited to Policyholder Accounts [medium — financial]: Interest credited to policyholder account balances rose to $6,608 million for the nine months ended September 30, 2025. This increase in the cost of funds for policyholder liabilities put pressure on margins.
• Allowance for Credit Loss on Mortgage Loans [medium — financial]: The allowance for credit loss on mortgage loans increased from $800 million at December 31, 2024, to $1,261 million at September 30, 2025. This indicates a perceived increase in credit risk within the mortgage loan portfolio.
• Market Volatility and Investment Performance [medium — market]: While net investment income increased to $16,635 million, the significant net derivative losses highlight the impact of market volatility on the company's financial results. Fluctuations in investment values and derivative positions pose ongoing risks.
• Regulatory Environment [medium — regulatory]: As a global financial services company, MetLife is subject to extensive regulation in various jurisdictions. Changes in regulatory requirements, capital standards, or compliance burdens could impact operations and profitability.
• Operational Risks [low — operational]: The company's operations involve complex systems and processes. Disruptions due to cyber incidents, system failures, or human error could lead to financial losses and reputational damage.
• Deferred Policy Acquisition Costs (DAC) and Value of Business Acquired (VOBA) [low — financial]: Deferred policy acquisition costs and value of business acquired increased to $21,175 million from $19,627 million. Changes in assumptions used to amortize these costs can impact reported earnings.

Industry Context

MetLife operates in the highly competitive global insurance and financial services industry. Key trends include evolving customer needs for protection and retirement solutions, increasing digitalization, and a persistent low-interest-rate environment impacting investment yields. Regulatory scrutiny remains high across major markets, requiring significant compliance efforts.

Regulatory Implications

MetLife faces a complex web of regulations globally, including capital requirements (e.g., Solvency II in Europe, NAIC RBC in the US) and consumer protection rules. Changes in accounting standards or new regulations could necessitate adjustments to business practices and impact financial reporting.

What Investors Should Do

1. Monitor derivative performance closely.
2. Analyze the drivers of increased policyholder benefits and claims.
3. Evaluate the impact of rising interest rates on investment income and liabilities.
4. Assess the adequacy of the allowance for credit losses.
5. Review segment performance disclosures in future filings.

Glossary

Fixed maturity securities available-for-sale

Investments in bonds and other debt instruments that the company intends to hold for an indefinite period but may sell in response to changes in interest rates, liquidity needs, or other factors. They are reported at fair value. (A significant portion of MetLife's investment portfolio, its value and performance directly impact the company's financial position and profitability.)

Net investment income

The income generated from the company's investment portfolio, including interest, dividends, and realized gains/losses on investments, net of investment expenses. (A primary driver of revenue for insurance companies; an increase here is positive, but it was offset by other factors.)

Net derivative losses

Losses incurred from financial instruments (like options, futures, swaps) used to manage risk or for speculative purposes. These can be volatile. (A significant negative contributor to net income in the current period, indicating increased market risk or hedging ineffectiveness.)

Policyholder account balances

The total amount of funds held by the company on behalf of policyholders, typically from annuity contracts or universal life policies. These represent liabilities for the company. (An increase indicates growth in customer deposits and business volume, but also represents a growing liability and cost of funds.)

Treasury stock acquired

The amount of the company's own stock that it has repurchased from the open market. This reduces the number of outstanding shares. (Indicates capital return to shareholders through buybacks, which can boost earnings per share.)

Preferred stock redemption

The process by which the company buys back its own preferred stock, reducing its outstanding preferred equity. (Can impact the company's capital structure and potentially reduce future dividend payments.)

Allowance for credit loss on mortgage loans

An estimate of the amount of loss expected from mortgage loans due to borrowers' inability to repay. It's a contra-asset account that reduces the carrying value of the loans. (An increase suggests rising credit risk in the mortgage portfolio, potentially impacting future earnings.)

Variable interest entities (VIEs)

Entities for which the company may have a significant financial interest but not a controlling voting interest. GAAP requires consolidation if the company is the primary beneficiary. (These entities can impact the company's consolidated assets, liabilities, and results of operations, requiring careful disclosure and analysis.)

Year-Over-Year Comparison

MetLife's nine-month performance shows a notable 19.8% decline in net income attributable to common shareholders, falling to $2.40 billion from $2.99 billion year-over-year. While total revenues saw a modest 1.8% increase to $53.27 billion, driven by higher net investment income ($16.64B vs $15.87B), this was significantly overshadowed by a near doubling of net derivative losses to $1.29 billion. Total assets grew by 6.2% to $719.73 billion, supported by increases in fixed maturity securities and policyholder account balances, but rising policyholder benefits and claims expenses also pressured profitability.

Key Financial Figures

• $0.01 M — ich registered Common Stock, par value $0.01 MET New York Stock Exchange Floating R

Filing Documents

• met-20250930.htm (10-Q) — 9116KB
• mlinc-2025930xex311.htm (EX-31.1) — 9KB
• mlinc-2025930xex312.htm (EX-31.2) — 8KB
• mlinc-2025930xex321.htm (EX-32.1) — 3KB
• mlinc-2025930xex322.htm (EX-32.2) — 3KB
• 0001099219-25-000230.txt ( ) — 42423KB
• met-20250930.xsd (EX-101.SCH) — 121KB
• met-20250930_cal.xml (EX-101.CAL) — 111KB
• met-20250930_def.xml (EX-101.DEF) — 1002KB
• met-20250930_lab.xml (EX-101.LAB) — 1582KB
• met-20250930_pre.xml (EX-101.PRE) — 1352KB
• met-20250930_htm.xml (XML) — 11989KB

— Financial Information

Part I — Financial Information Item 1. Financial Statements (Unaudited) (at September 30, 2025 and December 31, 2024 and for the Three Months and Nine Months Ended September 30, 2025 and 2024) Interim Condensed Consolidated Balance Sheets 4 Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) 5 Interim Condensed Consolidated Statements of Equity 6 Interim Condensed Consolidated Statements of Cash Flows 7 Notes to the Interim Condensed Consolidated Financial Statements: Note 1 — Business, Basis of Presentation and Summary of Significant Accounting Policies 8 Note 2 — Segment Information 10 Note 3 — Acquisition 16 Note 4 — Future Policy Benefits 16 Note 5 — Policyholder Account Balances 26 Note 6 — Market Risk Benefits 35 Note 7 — Separate Accounts 39 Note 8 — Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue 43 Note 9 — Reinsurance 44 Note 10 — Closed Block 44 Note 11 — Investments 47 Note 12 — Derivatives 63 Note 13 — Fair Value 75 Note 14 — Long-term Debt 90 Note 15 — Subordinated Debt Securities 91 Note 16 — Equity 92 Note 17 — Other Revenues and Other Expenses 97 Note 18 — Employee Benefit Plans 98 Note 19 — Income Tax 98 Note 20 — Earnings Per Common Share 99 Note 21 — Contingencies, Commitments and Guarantees 99 Note 22 — Subsequent Events 102

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 103

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 159

Controls and Procedures

Item 4. Controls and Procedures 160

— Other Information

Part II — Other Information

Legal Proceedings

Item 1. Legal Proceedings 161

Risk Factors

Item 1A. Risk Factors 161

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 161

Other Information

Item 5. Other Information 162

Exhibits

Item 6. Exhibits 163 Glossary 165

Signatures

Signatures 168 Table of Contents As used in this Form 10 Q, "MetLife," the "Company," "we," "our" and "us" refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. Note Regarding Forward-Looking Statements This Quarterly Report on Form 10Q, including Management's Discussion and Analysis of Financial Condition and Results of Operations, may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events and do not relate strictly to historical or current facts. They use words and terms such as "anticipate," "are confident," "assume," "believe," "continue," "could," "estimate," "expect," "if," "intend," "likely," "may," "plan," "potential," "project," "should," "target," "will," "would" and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. They include statements relating to strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. By their nature, forward-looking statements: speak only as of the date they are made; are not statements of historical fact or guarantees of future performance; and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Many factors determine Co

— Financial Information

Part I — Financial Information

Financial Statements

Item 1. Financial Statements MetLife, Inc. Interim Condensed Consolidated Balance Sheets September 30, 2025 and December 31, 2024 (Unaudited) (In millions, except share and per share data) September 30, 2025 December 31, 2024 Assets Investments: Fixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $ 248 and $ 160 , respectively); and amortized cost: $ 324,833 and $ 307,421 , respectively $ 304,645 $ 281,043 Equity securities, at estimated fair value 788 712 Contractholder-directed equity securities and fair value option securities, at estimated fair value 12,270 10,672 Mortgage loans (net of allowance for credit loss of $ 1,261 and $ 800 , respectively) 85,843 89,012 Policy loans 8,589 8,545 Real estate and real estate joint ventures (includes $ 382 and $ 378 , respectively, under the fair value option; $ 208 and $ 65 , respectively, of real estate held-for-sale; $ 296 and $ 183 , respectively, relating to variable interest entities) 13,932 13,342 Other limited partnership interests 14,741 14,378 Short-term investments, principally at estimated fair value 5,962 5,156 Other invested assets (includes $ 1,622 and $ 1,851 , respectively, of leveraged and direct financing leases; $ 517 and $ 424 , respectively, relating to variable interest entities) 16,932 18,504 Total investments 463,702 441,364 Cash and cash equivalents, principally at estimated fair value 20,233 20,068 Accrued investment income 3,791 3,489 Premiums, reinsurance and other receivables (includes $ 0 and $ 47 , respectively, relating to variable interest entities) 40,329 29,761 Market risk benefits, at estimated fair value 392 372 Deferred policy acquisition costs and value of business acquired 21,175 19,627 Current income tax recoverable 374 295 Deferred income tax asset 2,719 2,994 Goodwill 9,095 8,901 Other assets 11,572 11,082 Separate account assets 146,344 139,504 Total assets $ 719,726 $ 677,457 Liabilities

Business

Business "MetLife" and the "Company" refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. MetLife is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management. MetLife is organized into six segments: Group Benefits; Retirement and Income Solutions ("RIS"); Asia; Latin America; Europe, the Middle East and Africa ("EMEA"); and MetLife Holdings. In addition, the Company reports certain of its results of operations in Corporate & Other. See Note 2 for further information on the Company's segments and Corporate & Other. Basis of Presentation The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company's business and operations. Actual results could differ from these estimates. The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2024 consolidated balance sheet data was derived from audited consolidated financial statements included in MetLife, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2024 (the "2024 Annual Report"), which incl

View Full Filing

View this 10-Q filing on SEC EDGAR